News articles about Catalyst Biosciences (NASDAQ:CBIO) have been trending positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Biosciences earned a daily sentiment score of 0.29 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3194946010022 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media stories that may have effected Accern Sentiment’s rankings:

Shares of Catalyst Biosciences (NASDAQ CBIO) opened at $35.60 on Tuesday. The firm has a market capitalization of $186.91, a P/E ratio of -2.71 and a beta of 2.68. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $37.00.

A number of research analysts have commented on the stock. B. Riley set a $49.00 price target on shares of Catalyst Biosciences and gave the company a “buy” rating in a research report on Friday. ValuEngine raised Catalyst Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Catalyst Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, January 1st. Finally, Chardan Capital increased their price objective on Catalyst Biosciences from $10.00 to $75.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $37.50.

WARNING: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/positive-media-coverage-somewhat-unlikely-to-impact-catalyst-biosciences-cbio-stock-price.html.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.